Introduction
Canagliflozin is an orally administerable SGLT-2 Inhibitors. Canagliflozin is used in the treatment of Type – 2 Diabetic Patients. Canagliflozin retards the transporter protein SGLT-2 in kidneys. Canagliflozin decreases renal glucose reabsorption as a result urinary glucose secretes more. Canagliflozin has a lower risk of hypoglycaemia. Canagliflozin decreases the risk of heart attack, stroke or death in people who have diabetes type 2 suffering with heart and end-stage kidney disease.
Side effects of Canagliflozin
- Ketoacidosis
- Lower limb Amputations
- More thirst and more urination
- Nausea and vomiting
- Skin redness and itching
- Urinary tract infections
- Urosepsis and polynephritis
- Yeast infections and itching of vagina
- Bone Fracture
- Fatigue
- Fournier’s gangrene